Combined-modality therapy for rectal cancer: Future prospects

被引：4

作者：

Czito, Brian G.

Willett, Christopher G.

Bendell, Johanna C.

机构：

[1] Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA

[2] Duke Univ, Med Ctr, Div Transplantat & Oncol, Durham, NC 27710 USA

来源：

CLINICAL COLORECTAL CANCER | 2007年 / 6卷 / 09期

关键词：

bevacizumab; capecitabine; chemotherapy; epidermal growth factor receptor; irinotecan; oxaliplatin;

D O I：

10.3816/CCC.2007.n.030

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The management of rectal cancer has undergone significant evolution with advances in surgery, radiation therapy, and chemotherapy. These advances have translated into improved rates of local control, survival, and quality of life. More recently, the integration of newer chemotherapeutic and targeted agents in patients with advanced colorectal cancer have led to further improvements in disease-free survival and overall survival. These agents are now being studied with radiation therapy in the neoadjuvant therapy of rectal cancer.

引用

收藏

页码：625 / 633

页数：9

相关论文

共 89 条

[21] Epidermal growth factor receptor is a predictor of tumor response in locally advanced rectal cancer patients treated with preoperative radiotherapy [J].

Giralt, J ;

Eraso, A ;

Armengol, M ;

Rosselló, J ;

Majó, J ;

Ares, C ;

Espin, E ;

Benavente, S ;

de Torres, I .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 54 (05) :1460-1465

[22] A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study [J].

Glynne-Jones, R. ;

Falk, S. ;

Maughan, T. S. ;

Meadows, H. M. ;

Sebag-Montefiore, D. .

BRITISH JOURNAL OF CANCER, 2007, 96 (04) :551-558

[23] A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOX-RT) in patients with locally advanced rectal cancer [J].

Glynne-Jones, R ;

Sebag-Montefiore, D ;

Maughan, TS ;

Falk, SJ ;

McDonald, AC .

ANNALS OF ONCOLOGY, 2006, 17 (01) :50-56

[24] A Randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer [J].

Goldberg, RM ;

Sargent, DJ ;

Morton, RF ;

Fuchs, CS ;

Ramanathan, RK ;

Williamson, SK ;

Findlay, BP ;

Pitot, HC ;

Alberts, SR .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) :23-30

[25]

GUNDERSON LL, 1974, CANCER-AM CANCER SOC, V34, P1278, DOI 10.1002/1097-0142(197410)34:4<1278::AID-CNCR2820340440>3.0.CO

[26]

2-F

[27] Rectal cancer - The Basingstoke experience of total mesorectal excision, 1978-1997 [J].

Heald, RJ ;

Moran, BJ ;

Ryall, RDH ;

Sexton, R ;

MacFarlane, JK .

ARCHIVES OF SURGERY, 1998, 133 (08) :894-898

[28] THE HOLY PLANE OF RECTAL SURGERY [J].

HEALD, RJ .

JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 1988, 81 (09) :503-508

[29]

Hess S, 2000, P ARCR, V41, pA335

[30] Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer [J].

Hofheinz, Ralf-Dieter ;

Horisberger, Karoline ;

Woernle, Christoph ;

Wenz, Frederik ;

Kraus-Tiefenbacher, Uta ;

Kaehler, Georg ;

Dinter, Dietmar ;

Grobholz, Rainer ;

Heeger, Steffen ;

Post, Stefan ;

Hochhaus, Andreas ;

Willeke, Frank .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (05) :1384-1390

← 1 2 3 4 5 6 7 8 9 →